Wyeth Gets Exclusive License For Mochida's Painkiller Drug
This article was originally published in PharmAsia News
Executive Summary
Wyeth has acquired global rights to Mochida Pharmaceutical's preclinical transient receptor potential vanilloid sub-family 1 (TRPV-1) antagonist molecule for treating pain, the companies announced Jan 9. In return, Tokyo-based Mochida will be paid developmental milestones, an up-front fee and royalties on future sales. Full terms of the deal were not disclosed, but Mochida will retain co-development and co-marketing rights in Japan, according to the companies